Kalaris Therapeutics, Inc.

Kalaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing TH103, its lead product candidate for neovascular age-related macular degeneration (nAMD). The company was formed through the March 2025 merger with AlloVir, after which the combined company adopted the Kalaris Therapeutics name and Legacy Kalaris became its operating business.

12.23

12.23

— Kalaris Therapeutics, Inc.
%
Lead product candidate: TH103100% Clinical-stage biologic under development for nAMD and the company's main value driver.
Preclinical pipeline development0% Earlier-stage research and development work intended to expand the product pipeline beyond TH103.
Collaborations and licensing0% Strategic research, license, and sponsored-research arrangements that support development and IP access.

Kalaris does not yet sell commercial products; its current 'customers' are primarily clinical investigators, trial...

  • Clinical trial investigators and sitesprimary

    They run Phase 1a and Phase 1b/2 studies and are essential for generating safety and efficacy data.

  • Retina specialists / ophthalmologistsprimary

    Potential future prescribers of TH103 in nAMD if the product receives marketing approval.

  • Payers and reimbursement gatekeepersprimary

    They determine formulary access and pricing acceptance for a premium biologic versus biosimilars or generics.

  • Research collaborators and licensorssecondary

    Academic and industry partners that provide technology, IP, or sponsored research support.

The company is headquartered in the United States and its current development work is centered on U.S...

  • •United States is the core operating and regulatory market
  • •FDA pathway is the primary approval route for TH103
  • •Foreign regulators may matter if trials or approvals expand internationally
  • •No commercial geography yet because the company has no product sales
  • •Operations are concentrated in R&D, clinical, and corporate functions

Kalaris is focused on advancing TH103 through clinical development, protecting its intellectual property, and preparing...

01
Advance TH103 clinical developmentshort-term

Clinical data are the main value inflection point and the basis for future approval and commercialization.

02
Prepare for regulatory approval and commercializationmedium-term

The company has no sales infrastructure and must be ready to launch if TH103 is approved.

03
Strengthen IP and collaboration basemedium-term

Patent protection and external partnerships help defend the program and expand the pipeline.

Kalaris faces the classic risks of a clinical-stage biotech: trial failure, regulatory delay, and the possibility that...

critical

Clinical development failure for TH103

The company depends on one lead candidate, so weak safety or efficacy data would materially impair value.

Scope
Phase 1a and Phase 1b/2 nAMD trials
Materiality
high
high

Regulatory delay or denial

Approval depends on FDA and possibly foreign regulators, which may require additional studies or data.

Scope
TH103 approval pathway
Materiality
high
high

Single-source supplier dependence

A disruption in materials or components could delay trials and future manufacturing scale-up.

Scope
Clinical and commercial supply chain
Materiality
high
high

Financing and dilution risk

The company expects continued losses and will need substantial additional funding.

Scope
Operating runway and future capital raises
Materiality
high
medium

Commercialization execution risk

Kalaris has no sales, marketing, or distribution infrastructure and may struggle to launch efficiently.

Scope
Future U.S. launch of TH103
Materiality
medium
Fair value of derivative liabilities and convertible notes
Can materially affect reported net loss and period-to-period comparability
Accrued research and development expenses
Affects operating expenses and quarterly volatility
Stock-based compensation
Raises G&A and R&D expense without immediate cash outflow
Merger-related accounting
Can distort year-over-year comparisons around the closing date

KIORA PHARMACEUTICALS INC

KPRX · Pharmaceutical Preparations

Kairos Pharma, LTD.

KAPA · Pharmaceutical Preparations

Larimar Therapeutics, Inc.

LRMR · Pharmaceutical Preparations

Keros Therapeutics, Inc.

KROS · Pharmaceutical Preparations

KALA BIO, Inc.

KALA · Pharmaceutical Preparations

ALUMIS INC.

ALMS · Pharmaceutical Preparations

: 28/04/2026